Primaxin is a Small Molecule owned by Merck & Co, and is involved in 11 clinical trials, which were completed.

Imipenem is a pencillin-binding protein inhibitor. It binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes that are involved in the last stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. This inactivation results in the weakening of the bacterial cell wall and eventually causes cell lysis.
Cilastatin is a specific and reversible renal dehydropeptidase-I inhibitor. Since the antibiotic, imipenem is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness.

The revenue for Primaxin is expected to reach a total of $2.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Primaxin NPV Report.

Primaxin is currently owned by Merck & Co.

Primaxin Overview

Imipenem and cilastatin sodium (Primaxin, Tienam, Zienam) is a fixed dose combination drug consisting of broad spectrum antibacterial agents. It is formulated as injectable powder solution and solution for intramuscular and intravenous route of administration. It is indicated in the treatment of UTI, intra abdominal infections, endocarditis, septicemia, bone and joint infections, lower respiratory tract infections, genital infections, skin and skin structure infections, ventilator and hospital acquired pneumonia, febrile neutropenia, lung and liver abscess, cholangitis, cholecystitis, cystitis, pyelonephritis, peritonitis, pneumonia, acute bronchitis, empyema, wound prophylaxis, corneal ulcers, endopthalmitis, intra uterine infections, keratitis.

Merck & Co Overview

Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

The company reported revenues of (US Dollars) US$48,704 million for the fiscal year ended December 2021 (FY2021), an increase of 17.3% over FY2020. In FY2021, the company’s operating margin was 25.7%, compared to an operating margin of 12% in FY2020. In FY2021, the company recorded a net margin of 26.8%, compared to a net margin of 17% in FY2020. The company reported revenues of US$14,959 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.

Quick View – Primaxin

Report Segments
  • Innovator (NME)
Drug Name
  • Primaxin
Administration Pathway
  • Intramuscular
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Hematological Disorders
  • Infectious Disease
  • Musculoskeletal Disorders
  • Ophthalmology
  • Respiratory
Key Companies
  • Sponsor Company: Merck & Co
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.